C WorldWide Group Holding A S Purchases 50,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

C WorldWide Group Holding A S increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 19.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 303,851 shares of the biotechnology company’s stock after buying an additional 50,000 shares during the quarter. BioMarin Pharmaceutical accounts for approximately 0.4% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 26th largest position. C WorldWide Group Holding A S’s holdings in BioMarin Pharmaceutical were worth $29,297,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BMRN. Headlands Technologies LLC grew its position in shares of BioMarin Pharmaceutical by 950.0% in the 4th quarter. Headlands Technologies LLC now owns 1,281 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 1,159 shares during the last quarter. Atria Wealth Solutions Inc. lifted its stake in shares of BioMarin Pharmaceutical by 1.6% in the fourth quarter. Atria Wealth Solutions Inc. now owns 9,729 shares of the biotechnology company’s stock worth $938,000 after acquiring an additional 153 shares during the period. Yousif Capital Management LLC bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at approximately $214,000. Foundry Partners LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter valued at approximately $217,000. Finally, EFG Asset Management Americas Corp. raised its holdings in BioMarin Pharmaceutical by 1.6% during the 4th quarter. EFG Asset Management Americas Corp. now owns 27,228 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 432 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 35,341 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the sale, the insider now directly owns 212,117 shares in the company, valued at $18,068,126.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total value of $3,010,346.38. Following the transaction, the insider now directly owns 212,117 shares of the company’s stock, valued at approximately $18,068,126.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jean Jacques Bienaime sold 20,000 shares of the stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the sale, the director now directly owns 474,994 shares of the company’s stock, valued at approximately $43,347,952.44. The disclosure for this sale can be found here. Insiders have sold a total of 103,229 shares of company stock worth $9,062,967 in the last 90 days. 1.84% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Robert W. Baird dropped their price objective on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 30th. Wells Fargo & Company raised their target price on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday. Scotiabank boosted their price target on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $110.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $107.50.

BioMarin Pharmaceutical Price Performance

BMRN stock traded down $1.26 during mid-day trading on Friday, reaching $80.91. 2,257,132 shares of the company traded hands, compared to its average volume of 1,697,110. BioMarin Pharmaceutical Inc. has a 52-week low of $76.02 and a 52-week high of $99.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The company has a market capitalization of $15.27 billion, a P/E ratio of 75.62, a P/E/G ratio of 1.51 and a beta of 0.31. The company has a fifty day moving average price of $87.58 and a 200-day moving average price of $89.13.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.39% and a net margin of 8.31%. The company’s revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 earnings per share. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.85 earnings per share for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.